CION Ameerpet
Hormone replacement therapy (HRT) can transform life during menopause — but many women worry it causes breast cancer. The honest answer is nuanced: combined HRT slightly raises risk, oestrogen-only HRT behaves very differently, and for most women the rise is small and reduces after stopping. At CION, a woman-headed, tumor-board-led team helps you weigh symptom relief against your personal risk — clearly, without scare tactics or rushed decisions.
This is the question almost every woman starting menopause hormone therapy asks. The careful answer from large studies is that HRT does not 'cause' breast cancer in a simple way — but some types can slightly increase the risk of developing it. The effect depends heavily on which kind of HRT you take, how long you take it, and your starting age.
To put the scale in perspective: research bodies estimate that around 2 in every 100 breast cancers are linked to HRT use. For most healthy women in their late 40s and 50s, the increase in absolute risk from a few years of HRT is small, and it has to be weighed against genuine benefits — relief from hot flushes and night sweats, better sleep and mood, and protection of bone strength. The goal is not fear; it is an informed, individual decision made with a doctor who knows your history.
Breast cancers in the population are estimated to be linked to HRT use — most cases have nothing to do with it.
Combined (oestrogen + progestogen) HRT raises risk more than oestrogen-only HRT, which behaves very differently.
The increased risk from HRT reduces over time once you stop — it does not stay raised forever.
Not all HRT carries the same breast cancer risk. In the Women's Health Initiative, combined oestrogen-plus-progestogen HRT was linked to roughly 3 extra cases of invasive breast cancer per 1,000 women over about five years — yet oestrogen-only HRT (for women who have had a hysterectomy) showed little or no increase, and in some groups even a lower risk. The mean age of menopause in India is around 46, so the type, dose and timing of HRT matter for Indian women. Source: Women's Health Initiative / NCCN.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
One of the most important things to understand is that not all HRT is the same. The biggest difference in breast cancer risk is between combined HRT (oestrogen plus a progestogen, given to women who still have a uterus) and oestrogen-only HRT (given to women who have had a hysterectomy). Whether the progestogen is taken every day (continuous) or for part of the month (cyclical) also makes a difference.
Knowing which type you are on — and why — is the first step in understanding your own risk. If you are unsure, this is exactly the kind of question a 45-minute consultation is built to answer.
Oestrogen-plus-progestogen HRT is the type most clearly linked to a slightly higher breast cancer risk, especially when used for more than five years. Continuous combined regimens tend to carry a little more risk than cyclical ones.
For women who have had a hysterectomy, oestrogen-only HRT shows little or no increase in breast cancer risk in major studies — and in the Women's Health Initiative follow-up it was even associated with a lower risk in some groups. It cannot be used if you still have a uterus, because oestrogen alone raises womb-cancer risk.
Low-dose vaginal oestrogen used only for vaginal dryness acts locally and is not considered to raise breast cancer risk in the way systemic HRT can.
Higher-dose formulations tend to carry more risk than lower-dose ones. The lowest effective dose for the shortest needed time is the guiding principle.
Numbers help replace worry with perspective. The increase in breast cancer risk from HRT builds with the duration of use and is more noticeable after about five years. Crucially, it is not a one-way street: once you stop HRT, the added risk falls again over time — and the longer you used it, the longer that fall takes.
Two figures are widely cited. The Women's Health Initiative found roughly 3 extra cases of invasive breast cancer per 1,000 women who took combined oral HRT for about five years. UK estimates suggest around a 2.3% relative increase for each year of combined HRT use. Both confirm the same picture: a real but modest rise, concentrated in longer use and older starting age.
Approximate excess invasive breast cancers seen with about five years of combined oral HRT in the Women's Health Initiative — a small absolute number for most women.
The increase is more noticeable beyond five years of combined HRT, and is higher when HRT is started at an older age, when background breast cancer risk is already rising naturally.
When combined HRT is stopped, the added risk goes down over the following years. For women who used it for less than five years, studies suggest little measurable excess risk remains a few years after stopping.
Because oestrogen-only HRT shows little or no added risk to begin with, the 'reversal' question is far less of a concern for women on this type.
HRT exists because menopause symptoms are not trivial. Hot flushes, night sweats, disturbed sleep, mood changes, vaginal dryness and accelerated bone loss can seriously affect quality of life and long-term health. The decision is rarely 'risk vs no risk' — it is about weighing a small, often temporary breast cancer risk against real, daily relief and genuine bone protection.
For many healthy women within ten years of menopause or under 60, with no contraindications, the balance can favour HRT. For others, the balance tips the other way. This is a personal calculation — and one a specialist should make with you, in plain language, not for you.
Hot flushes and night sweats, sleep and mood disturbance, vaginal dryness, joint aches, and protection against osteoporosis and fractures — these are well-established benefits, not marketing claims.
Evidence suggests HRT is generally safest and most beneficial when started within about ten years of menopause or before age 60, in women without contraindications. The mean age of menopause in India is around 46, so this window matters for Indian women.
Family history, breast density, previous biopsies, lifestyle and overall health all shift the balance. The same HRT carries a different meaning for two different women.
Where HRT is appropriate, using the lowest effective dose for the shortest period that controls symptoms keeps the risk as low as possible while preserving the benefit.
An HRT decision sits at the crossroads of gynaecology and oncology — which is exactly why a tumor-board-led, woman-headed organisation is the right place to have the conversation. CION does not sell you HRT and does not frighten you out of it. We give you the evidence, your personal risk, and an honest recommendation.
17 super-specialist oncologists across medical, surgical and radiation oncology — so your HRT and breast risk are assessed by people who treat breast cancer, not just prescribe hormones.
If you have a family history, a past breast finding, or a current diagnosis, your case can be reviewed by 3+ specialists together before any HRT advice is given.
A woman-led organisation with a 45-minute first consultation, clear costs, and no unnecessary tests — decisions for healing, not billing.
A 4.8/5 Google rating across centres in Telangana and AP, with screening and diagnostics available close to home.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumor-board-reviewed, confidential care across 35+ centres in Telangana & AP. Call 1800-202-8726.
For two groups of women, the HRT conversation is more cautious. If you have a strong family history of breast cancer — or a known BRCA1/BRCA2 mutation — your background risk is already higher, and systemic HRT needs careful, individualised discussion. If you have already had breast cancer, the picture is more restrictive still.
For most breast cancer survivors, systemic HRT is generally not recommended, because there is real concern it could raise the chance of the cancer returning — one study reported around an 80% higher recurrence risk in women with hormone-receptor-positive disease who used systemic HRT. This does not mean nothing can be done for symptoms; it means the safer, non-hormonal options below come first, decided with your oncologist.
Breast or ovarian cancer in close relatives, especially at a young age, raises your background risk. HRT is not automatically off the table, but the decision needs a specialist review and often genetic counselling first.
Women with a BRCA1/BRCA2 mutation have a substantially higher lifetime breast cancer risk; any HRT decision must be individualised and discussed with an oncology team, particularly after risk-reducing surgery.
Systemic HRT is usually avoided in breast cancer survivors — especially hormone-receptor-positive cancers — because of the concern it may increase recurrence. Non-hormonal symptom control is the preferred route.
The Gail and similar Western risk models perform poorly in Indian women, so risk assessment here relies more on detailed history, examination and specialist judgement — another reason to be seen in person.
If HRT is not right for you — or you would rather try other routes first — there are effective options. And if you do choose HRT, monitoring keeps it as safe as possible. The aim is to control symptoms while keeping a clear eye on your breasts over time. No alternative is one-size-fits-all; a specialist can match the approach to your symptoms, your risk and your preferences — and set up the right surveillance schedule.
Certain non-hormonal prescription medicines (for example SSRIs/SNRIs, gabapentin, and newer agents such as fezolinetant) can reduce hot flushes for women who cannot or prefer not to take HRT. These are prescribed and reviewed by a doctor.
Low-dose vaginal oestrogen, or non-hormonal moisturisers and lubricants, treat vaginal dryness without the systemic exposure of full HRT — a low-risk option for many women.
Regular weight-bearing exercise, a calcium- and vitamin-D-adequate diet, limiting alcohol, stopping smoking, and managing weight all reduce both symptoms and background breast cancer risk.
Women on HRT should keep up with recommended breast screening. Be breast-aware between visits and report any new lump, skin or nipple change promptly rather than waiting.
If you take HRT, plan a regular review of whether you still need it, at what dose, and for how much longer — HRT is meant to be reassessed, not left on autopilot.
You do not have to make the HRT decision alone, and you do not have to choose between symptom relief and peace of mind. CION offers clear, woman-led risk counselling and breast screening so you can decide with full information — your first consultation is free.
A specialist reviews your symptoms, age, HRT type and family history, and explains your personal breast cancer risk in plain language — no rushed decisions, no unnecessary tests.
We look at your history, breast density and any past findings together, since no single Indian risk calculator is reliable — and recommend screening that fits your risk.
Clinical breast examination, ultrasound or mammography as appropriate, across 35+ centres in Telangana and AP, with up to 50% discounts on diagnostics.
Whether to start, continue, lower or stop HRT — or use a non-hormonal alternative — decided with you, and reviewed by the tumor board for complex cases.
For the small number of women in whom screening or symptoms do reveal a breast cancer, early, team-based treatment changes the result. The HRT question becomes secondary to getting the right diagnosis and the right plan, fast. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Outcomes are tied closely to the stage at diagnosis — which is why staying breast-aware and screened while on HRT matters.
Accurate hormone-receptor and HER2 testing lets the team match modern targeted and hormone therapies to your specific cancer — and decide whether HRT must stop.
A tumor-board approach reduces the chance of an avoidable misstep, and keeps your menopause symptoms in view alongside cancer treatment.
*1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP). CION figures are network outcomes; national figures are population averages and do not predict an individual's result.
Hear from women counselled and treated at CION — how they weighed symptoms, risk, and what they decided.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.HRT does not 'cause' breast cancer in a simple, direct way, but some types can slightly increase the risk of developing it. The clearest effect is with combined HRT (oestrogen plus progestogen) used for more than about five years. Oestrogen-only HRT, taken by women who have had a hysterectomy, shows little or no increase in major studies. Overall, only around 2 in every 100 breast cancers are estimated to be linked to HRT, and for most healthy women starting near menopause the absolute rise in risk is small. The right decision depends on your type of HRT, how long you use it, your age, and your personal risk — which is best assessed with a specialist.
For breast cancer risk, oestrogen-only HRT is generally the lower-risk option, but it can only be used by women who have had a hysterectomy, because oestrogen alone raises womb (endometrial) cancer risk in women who still have a uterus. Combined HRT — oestrogen plus a progestogen — is needed to protect the womb, but it is the type most clearly linked to a small increase in breast cancer risk, especially after five years of use. Low-dose vaginal oestrogen used only for dryness acts locally and is considered low risk. The 'safer' choice depends on whether you have a uterus and your overall risk profile, so it should be individualised with a doctor.
The increase is modest and builds with duration of use. The Women's Health Initiative found roughly 3 extra cases of invasive breast cancer per 1,000 women who took combined oral HRT for about five years. UK estimates suggest around a 2.3% relative increase for each year of combined HRT use, with risk more noticeable beyond five years and when HRT is started at an older age. Oestrogen-only HRT shows little or no added risk. These are population averages — your individual risk depends on family history, breast density, and other factors, so a personal assessment gives a far more meaningful number than a headline statistic.
Yes, the added risk reduces over time after you stop HRT — it does not stay raised permanently. The fall is faster for shorter use: studies suggest that for women who took combined HRT for less than about five years, little measurable excess risk remains a few years after stopping. The longer you used HRT, the longer it takes for the risk to return toward baseline. This is one reason doctors recommend using the lowest effective dose for the shortest time that controls your symptoms, and reviewing regularly whether you still need it.
A family history of breast cancer does not automatically rule out HRT, but it does mean the decision needs careful, individualised review. Your background risk is already higher, so a specialist will weigh the severity of your menopause symptoms against your personal risk, and may recommend genetic counselling — particularly if relatives were diagnosed young or there is a known BRCA mutation. For some women with a strong family history, non-hormonal alternatives or local vaginal oestrogen are preferred. At CION, this assessment can include a tumor-board review, so the advice comes from a team that treats breast cancer rather than a single prescriber.
For most breast cancer survivors, systemic HRT is generally not recommended, because of concern that it may increase the chance of the cancer returning — one study reported around an 80% higher recurrence risk in women with hormone-receptor-positive disease who used systemic HRT. This is especially the case for hormone-receptor-positive cancers. It does not mean your menopause symptoms must go untreated: non-hormonal medicines, low-dose local vaginal oestrogen for dryness, and lifestyle measures are the preferred options, decided together with your oncologist. Any exception is a specialist-only decision based on your specific cancer and circumstances.
Several effective non-hormonal options exist. For hot flushes, certain prescription medicines such as SSRIs/SNRIs, gabapentin, and newer agents like fezolinetant can help. For vaginal dryness, low-dose vaginal oestrogen or non-hormonal moisturisers and lubricants work locally with minimal systemic exposure. Lifestyle measures — regular weight-bearing exercise, a calcium- and vitamin-D-rich diet, limiting alcohol, stopping smoking, and managing weight — ease symptoms and lower background breast cancer risk, while protecting bone health. The best combination depends on which symptoms trouble you most and your overall risk, which a specialist can help you map out.
Yes. Women on HRT should continue with recommended breast screening and stay breast-aware between appointments. Because HRT can slightly increase breast density and risk, keeping up regular clinical breast examination and mammography or ultrasound as advised is important, and any new lump, skin change or nipple change should be reported promptly rather than watched for months. At CION, breast screening is available across 35+ centres in Telangana and AP, with up to 50% discounts on diagnostics, so monitoring while on HRT is straightforward and close to home.
Yes. CION offers a free first consultation for all cancer patients, including women trying to decide whether HRT is safe for them. It is a full 45-minute consultation in which a specialist reviews your symptoms, age, HRT type and family history, explains your personal breast cancer risk in plain language, and gives an honest recommendation — to start, continue, lower, stop, or use a non-hormonal alternative. Complex cases can be reviewed by the tumor board. You can book on 1800-202-8726 or request a callback through the form on this page.